ALRN-6924 Dose plus TAC for Prevention of Chemotherapy-induced Myelosuppression

"Due to the limited data available on ALRN-6924 Dose plus TAC, our team at Power gave it a safety score of 1. This is reflective of its status as a Phase 1 trial without any clinical evidence for efficacy or security."

"Aileron Therapeutics, Inc., the trial sponsor in question, has outlined several objectives for this study. Over a period of 24 weeks, their primary aim is to assess ALRN-6924's ability to protect bone marrow from toxicities. Secondary outcomes include an evaluation of the drug's pharmacokinetics (PK), how many platelet transfusions are needed during each cycle and over all cycles combined, as well as its chemoprotective effects on neutropenia across multiple treatment cycles."

"The clinicaltrial.gov site indicates that this medical trial is in progress and actively recruiting patients. The investigation was posted on November 1st 2022, with updates taking place as recently as the 16th of the same month."

"Affirmative. Clinicaltrials.gov reveals that the trial, first posted on November 1st 2022 and last amended on the 16th of the same month is actively recruiting participants for enrollment; 26 individuals need to be recruited from 5 distinct sites."

"Presently, this clinical trial is inviting participants to join from 5 different medical centres. Canton, Gettysburg and Huntersville are amongst the locations where recruitment is taking place. As such it would be sensible for applicants to choose a clinic closest them in order to reduce their travelling requirements should they decide to participate."